MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

CureVac NV

Ouvert

3.36 5

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.19

Max

3.38

Chiffres clés

By Trading Economics

Revenu

-409M

-39M

Ventes

-479M

14M

P/E

Moyenne du Secteur

3.915

57.333

BPA

-0.156

Marge bénéficiaire

-266.508

Employés

825

EBITDA

-410M

-35M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+63.09% upside

Dividendes

By Dow Jones

Prochains Résultats

22 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-14M

723M

Ouverture précédente

-1.64

Clôture précédente

3.36

Score Technique

By Trading Central

Confiance

Bullish Evidence

CureVac NV Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juil. 2024, 09:14 UTC

Acquisitions, Fusions, Rachats

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

3 juil. 2024, 14:18 UTC

Acquisitions, Fusions, Rachats

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 juil. 2024, 09:38 UTC

Market Talk

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Comparaison

Variation de prix

CureVac NV prévision

Objectif de Prix

By TipRanks

63.09% hausse

Prévisions sur 12 Mois

Moyen 5.17 USD  63.09%

Haut 10 USD

Bas 2.5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

3 ratings

1

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

3.19 / 3.27Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.